Published in J Clin Invest on August 01, 1984
Control of globin gene expression during development and erythroid differentiation. Exp Hematol (2005) 3.47
How I use hydroxyurea to treat young patients with sickle cell anemia. Blood (2010) 2.68
Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest (2007) 2.47
Fetal hemoglobin in sickle cell anemia. Blood (2011) 2.44
Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest (1996) 2.31
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest (2003) 2.00
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
Advances in the understanding of haemoglobin switching. Br J Haematol (2010) 1.74
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
Regulation of human fetal hemoglobin: new players, new complexities. Blood (2005) 1.60
Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood (2012) 1.58
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest (2008) 1.50
The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med (2013) 1.47
Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood (2015) 1.43
Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood (2004) 1.34
Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood (2003) 1.23
Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol (2011) 1.18
Methylation-enhanced binding of Sp1 to the stage selector element of the human gamma-globin gene promoter may regulate development specificity of expression. Mol Cell Biol (1993) 1.04
Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest (1997) 1.02
Effects of DNA and prostaglandin synthesis inhibitors on the stimulation of bone resorption by epidermal growth factor in fetal rat long-bone cultures. J Clin Invest (1986) 1.01
The rationale for using hydroxycarbamide in the treatment of sickle cell disease. Haematologica (2011) 1.01
LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. Blood (2013) 1.00
Eukaryotic initiation factor 2α phosphorylation mediates fetal hemoglobin induction through a post-transcriptional mechanism. Blood (2013) 1.00
Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol (2011) 0.99
Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am (2010) 0.98
MicroRNA-96 directly inhibits γ-globin expression in human erythropoiesis. PLoS One (2011) 0.95
Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer (2012) 0.93
Update on the use of hydroxyurea therapy in sickle cell disease. Blood (2014) 0.93
Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J Clin Invest (1985) 0.91
A pilot study of subcutaneous decitabine in β-thalassemia intermedia. Blood (2011) 0.88
Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease. Exp Biol Med (Maywood) (2016) 0.88
Current management of sickle cell anemia. Cold Spring Harb Perspect Med (2013) 0.87
Epigenetic regulation of fetal globin gene expression in adult erythroid cells. Transl Res (2014) 0.87
Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea. J Clin Invest (1988) 0.87
Induction of fetal hemoglobin through enhanced translation efficiency of γ-globin mRNA. Blood (2014) 0.87
Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. Blood (2011) 0.86
Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era. Exp Biol Med (Maywood) (2016) 0.86
Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial. Am J Hematol (2015) 0.85
Customizing the genome as therapy for the β-hemoglobinopathies. Blood (2016) 0.85
Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica (2013) 0.84
Variation in Gamma-Globin Expression before and after Induction with Hydroxyurea Associated with BCL11A, KLF1 and TAL1. PLoS One (2015) 0.84
Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood Transfus (2010) 0.83
National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008. Med Care (2014) 0.83
LIN28A expression reduces sickling of cultured human erythrocytes. PLoS One (2014) 0.82
From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine (Baltimore) (2014) 0.82
Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. PLoS One (2015) 0.81
Pluripotent stem cells in research and treatment of hemoglobinopathies. Cold Spring Harb Perspect Med (2012) 0.81
Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice. Blood (2015) 0.80
Advances in sickle cell therapies in the hydroxyurea era. Mol Med (2014) 0.80
A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Rev Hematol (2015) 0.80
Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cells. PLoS One (2014) 0.79
Mapping polymerization and allostery of hemoglobin S using point mutations. J Phys Chem B (2013) 0.79
Sickle Cell Disease: Reappraisal of the Role of Foetal Haemoglobin Levels in the Frequency of Vaso-Occlusive Crisis. Ghana Med J (2015) 0.79
Determination of the transition-state entropy for aggregation suggests how the growth of sickle cell hemoglobin polymers can be slowed. J Mol Biol (2008) 0.78
Nucleotide Pool Depletion Induces G-Quadruplex-Dependent Perturbation of Gene Expression. Cell Rep (2015) 0.78
The pulmonary physician in critical care * Illustrative case 6: Acute chest syndrome of sickle cell anaemia. Thorax (2003) 0.77
Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation. Am J Hematol (2015) 0.77
Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease. Ther Clin Risk Manag (2009) 0.76
Cis-vaccenic acid induces differentiation and up-regulates gamma globin synthesis in K562, JK1 and transgenic mice erythroid progenitor stem cells. Eur J Pharmacol (2016) 0.76
Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease. Exp Biol Med (Maywood) (2015) 0.76
Hydroxycarbamide: clinical aspects. C R Biol (2012) 0.76
Treatment for sickle cell disease in Africa: should we invest in haematopoietic stem cell transplantation? Pan Afr Med J (2014) 0.76
Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease. Proc Natl Acad Sci U S A (2017) 0.76
Sickle cell disease and H3Africa: enhancing genomic research on cardiovascular diseases in African patients. Cardiovasc J Afr (2015) 0.76
Safety and efficacy of hydroxyurea in children and adolescents with sickle/beta-thalassemia: two-year experience. Hippokratia (2016) 0.75
An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine. OMICS (2016) 0.75
Hydroxyurea and colonic ulcers: a case report. BMC Gastroenterol (2014) 0.75
The Effect of Hydroxyurea Therapy in Bahraini Sickle Cell Disease Patients. Indian J Hematol Blood Transfus (2015) 0.75
2006 Association of American Physicians George M. Kober Medal. Introduction of David G. Nathan, MD. J Clin Invest (2007) 0.75
Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania. BMC Med Res Methodol (2016) 0.75
Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease. Mediterr J Hematol Infect Dis (2017) 0.75
Hemoglobin switching in humans is accompanied by changes in the ratio of the transcription factors, GATA-1 and SP1. Mol Med (1995) 0.75
Nitric Oxide-cGMP Signaling Stimulates Erythropoiesis through Multiple Lineage-Specific Transcription Factors: Clinical Implications and a Novel Target for Erythropoiesis. PLoS One (2016) 0.75
The novelty of research article: Whose responsibility is it? Indian J Pharmacol (2011) 0.75
Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Res Protoc (2017) 0.75
Induced Pluripotent Stem Cell for the Study and Treatment of Sickle Cell Anemia. Stem Cells Int (2017) 0.75
Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol (1975) 503.08
Polymorphic DNA region adjacent to the 5' end of the human insulin gene. Proc Natl Acad Sci U S A (1981) 12.86
DNA methylation in the human gamma delta beta-globin locus in erythroid and nonerythroid tissues. Cell (1980) 8.41
DNA methylation and the regulation of globin gene expression. Cell (1983) 6.49
Insertion of synthetic copies of human globin genes into bacterial plasmids. Nucleic Acids Res (1978) 5.99
Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol (1974) 4.92
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med (1982) 3.29
Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells. Proc Natl Acad Sci U S A (1977) 2.43
Gene amplification in a single cell cycle in Chinese hamster ovary cells. J Biol Chem (1984) 2.32
Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood (1984) 2.24
5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A (1982) 2.19
DNA methylation--how important in gene control? Nature (1984) 2.14
Fetal haemoglobin production and the sickle gene in the oases of Eastern Saudi Arabia. Br J Haematol (1978) 1.98
Hydroxyurea. Mutat Res (1975) 1.77
Methylation and gene control. Nature (1982) 1.70
Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci U S A (1983) 1.60
Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem (1980) 1.58
Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med (1984) 1.54
Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. Science (1984) 1.36
Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5-azacytidine. Blood (1984) 1.33
Microscopic method for assaying F cell production: illustrative changes during infancy and in aplastic anemia. Blood (1978) 1.15
Hereditary persistence of fetal hemoglobin. A family study. Am J Med (1960) 1.12
Erythroid differentiation in cultured Friend leukemia cells treated with metabolic inhibitors. Cancer Res (1976) 0.98
Radio-ligand immunoassay for human hemoglobin variants. J Immunol Methods (1981) 0.92
Determinations of fetal hemoglobin in whole blood, using a modified alkali denaturation test. Am J Clin Pathol (1958) 0.86
Hydroxyurea-induced erythroid differentiation. Proc Soc Exp Biol Med (1975) 0.85
DNA synthesis inhibition and cell death associated with hydroxyurea teratogenesis in rat embryos. Dev Biol (1971) 0.84
Epigenetic memory in induced pluripotent stem cells. Nature (2010) 14.31
Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature (1991) 10.30
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Linkage of beta-thalassaemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster. Nature (1982) 9.47
Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature (1989) 9.08
Molecular drive: a cohesive mode of species evolution. Nature (1982) 8.79
An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature (1994) 8.60
The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ (2007) 7.74
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Positive and negative elements regulate human interleukin 3 expression. Proc Natl Acad Sci U S A (1990) 7.44
Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet (1995) 7.34
Quantitative nitroblue tetrazolium test in chronic granulomatous disease. N Engl J Med (1968) 6.91
Specific transcription and RNA splicing defects in five cloned beta-thalassaemia genes. Nature (1983) 6.48
Cloning the gene for an inherited human disorder--chronic granulomatous disease--on the basis of its chromosomal location. Nature (1986) 6.34
Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci U S A (1999) 6.29
FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell (1997) 5.78
The mutation and polymorphism of the human beta-globin gene and its surrounding DNA. Annu Rev Genet (1984) 5.74
Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature (1995) 5.42
Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med (1994) 5.32
E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell (1996) 5.26
Activity and tissue-specific expression of the transcription factor NF-E1 multigene family. Genes Dev (1990) 5.25
Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science (1985) 5.23
Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev (1994) 5.22
Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A (1996) 5.20
Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature (1990) 5.13
Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature (1984) 5.10
Rate of turnover of structural variants in the rDNA gene family of Drosophila melanogaster. Nature (1982) 5.09
Lethal beta-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature (1995) 4.97
A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell (1998) 4.78
Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein. Nature (1993) 4.68
A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J (1997) 4.61
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol (2001) 4.54
School-based programs to reduce sexual risk behaviors: a review of effectiveness. Public Health Rep (1994) 4.50
Transcriptional activation and DNA binding by the erythroid factor GF-1/NF-E1/Eryf 1. Genes Dev (1990) 4.35
The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell (1996) 4.35
Application of endonuclease mapping to the analysis and prenatal diagnosis of thalassemias caused by globin-gene deletion. N Engl J Med (1978) 4.34
DNA-binding specificity of GATA family transcription factors. Mol Cell Biol (1993) 4.34
Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell (1995) 4.32
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Leukocyte oxidase: defective activity in chronic granulomatous disease. Science (1967) 4.25
Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res (1987) 4.25
An essential role in liver development for transcription factor XBP-1. Genes Dev (2000) 4.17
Mouse GATA-4: a retinoic acid-inducible GATA-binding transcription factor expressed in endodermally derived tissues and heart. Mol Cell Biol (1993) 4.13
Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line. Mol Cell Biol (1997) 4.12
Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature (1990) 3.96
Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. Blood (2001) 3.93
Increased gamma-globin expression in a nondeletion HPFH mediated by an erythroid-specific DNA-binding factor. Nature (1989) 3.76
The transcriptional control of hematopoiesis. Blood (1996) 3.72
Functional analysis and in vivo footprinting implicate the erythroid transcription factor GATA-1 as a positive regulator of its own promoter. Genes Dev (1991) 3.61
Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature (1986) 3.50
Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet (2000) 3.50
School-based screening for tuberculous infection. A cost-benefit analysis. JAMA (1995) 3.47
Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with the Krüppel family proteins Sp1 and EKLF. Mol Cell Biol (1995) 3.39
Isolation and DNA sequence of a full-length cDNA clone for human X chromosome-encoded phosphoglycerate kinase. Proc Natl Acad Sci U S A (1983) 3.33
The duplicated human alpha globin genes lie close together in cellular DNA. Proc Natl Acad Sci U S A (1978) 3.33
CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. Proc Natl Acad Sci U S A (1998) 3.22
Are amyotrophic lateral sclerosis patients cognitively normal? Neurology (2003) 3.21
Novel blunt-end addition reactions catalyzed by DNA polymerase I of Escherichia coli. J Mol Biol (1987) 3.16
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood (1992) 3.09
GATA transcription factors: key regulators of hematopoiesis. Exp Hematol (1995) 3.09
Differentiation in erythroleukemic cells and their somatic hybrids. Proc Natl Acad Sci U S A (1975) 3.05
Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev (1998) 3.00
Human GATA-3: a lineage-restricted transcription factor that regulates the expression of the T cell receptor alpha gene. EMBO J (1991) 3.00
Development of homozygosity for chromosome 11p markers in Wilms' tumour. Nature (1984) 2.97
Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci U S A (2000) 2.91
Cultured human endothelial cells express platelet-derived growth factor B chain: cDNA cloning and structural analysis. Nature (1985) 2.87
FOG-2, a cofactor for GATA transcription factors, is essential for heart morphogenesis and development of coronary vessels from epicardium. Cell (2000) 2.86
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res (1997) 2.83
Development of hematopoietic cells lacking transcription factor GATA-1. Development (1995) 2.78
Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci U S A (1995) 2.78
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
Breast cancer among black and white women in the 1980s. Changing patterns in the United States by race, age, and extent of disease. Cancer (1993) 2.70
Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo. Proc Natl Acad Sci U S A (1986) 2.69
The major human erythroid DNA-binding protein (GF-1): primary sequence and localization of the gene to the X chromosome. Proc Natl Acad Sci U S A (1990) 2.68
Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells. Nat Genet (1992) 2.66
Use of altered specificity mutants to probe a specific protein-protein interaction in differentiation: the GATA-1:FOG complex. Mol Cell (1999) 2.66
Improved detection of the sickle mutation by DNA analysis: application to prenatal diagnosis. N Engl J Med (1982) 2.64
Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA (1991) 2.64
The ubiquitous subunit of erythroid transcription factor NF-E2 is a small basic-leucine zipper protein related to the v-maf oncogene. Proc Natl Acad Sci U S A (1993) 2.63
GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood (1999) 2.62
Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency. EMBO J (2001) 2.62
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood (1999) 2.61
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood (1999) 2.59
A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci U S A (1997) 2.55
Dynamics of concerted evolution of ribosomal DNA and histone gene families in the melanogaster species subgroup of Drosophila. J Mol Biol (1982) 2.54
Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. Nature (1995) 2.50
Globin chain synthesis in the alpha thalassemia syndromes. J Clin Invest (1969) 2.46
The molecular basis of alpha-thalassemias: frequent occurrence of dysfunctional alpha loci among non-Asians with Hb H disease. Cell (1979) 2.41
Treatment of Cooley's anemia. Blood (1990) 2.40
The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature (1987) 2.38
Disorders of phagocytic cell function. Prog Hematol (1971) 2.37
Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature (1986) 2.36
Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells. J Biol Chem (1992) 2.35
Human adenosine deaminase. cDNA and complete primary amino acid sequence. J Biol Chem (1984) 2.33
Human erythroid burst-forming unit: T-cell requirement for proliferation in vitro. J Exp Med (1978) 2.33
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33